Registry for patients with immune-mediated thrombotic thrombocytopenic purpura in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ItaliTTP registry is an observational, prospective, multicenter study that aims to better understand the natural history and clinical outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in Italy. It will enroll at least 132 patients experiencing either their first episode or a relapse of iTTP over a three-year period, with follow-up extending for another three years. Participants will undergo routine clinical assessments and laboratory tests, including ADAMTS13 analysis, to gather comprehensive data on disease severity and progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with an acute iTTP episode (first event or relapse), defined by thrombocytopenia and microangiopathic hemolytic anemia, in the absence of alternative causes, and the presence of severe deficiency of ADAMTS13 activity (\< 10 IU/dL or \<10% of normal value) and anti-ADAMTS13 autoantibodies
* Both male and female patients, aged 12 years or older
* Patients who have signed the informed consent for the participation to the study

Exclusion Criteria:

* Patients who have not signed the informed consent for the participation to the study

Where it's running

• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  Milan, Mi, Italy Recruiting

Study contacts

• Principal investigator: Flora Peyvandi, MD, PhD — Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
• Study coordinator: Sandra Maccarone
• Email: contact@fondazioneluigivilla.org
• Phone: +39 02 551 0709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with Thrombotic Thrombocytopenic Purpura in Turkey

  This study is collecting information from patients with Thrombotic Thrombocytopenic Purpura in Turkey to see how the disease is treated and how it affects their health over time.

  Recruiting Turkish Hematology Association · Ankara · NCT05950750

• Creating a database for patients with Thrombotic Thrombocytopenic Purpura

  This study is creating a detailed database of information about patients with Thrombotic Thrombocytopenic Purpura to help better understand the condition.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT05571774

• cTTP patients treated with recombinant ADAMTS13: what happened after the early access program

  This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.

  Recruiting Takeda · Cologne, North Rhine-Westphalia and 7 other locations · NCT07429942

• Adzynma in people with congenital TTP: a look at safety and antibody risk

  This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.

  Recruiting at 6 sites Takeda · Vienna and 6 other locations · NCT07353099

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

• Understanding the immune response in Thrombotic Thrombocytopenic Purpura

  This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.

  Recruiting University Hospital, Rouen · Rouen · NCT06945861

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.